2024
Evaluation and Surgical Management of Pediatric Cutaneous Melanoma and Atypical Spitz and Non-Spitz Melanocytic Tumors (Melanocytomas): A Report From Children's Oncology Group
Sargen M, Barnhill R, Elder D, Swetter S, Prieto V, Ko J, Bahrami A, Gerami P, Karunamurthy A, Pappo A, Schuchter L, LeBoit P, Yeh I, Kirkwood J, Jen M, Dunkel I, Durham M, Christison-Lagay E, Austin M, Aldrink J, Mehrhoff C, Hawryluk E, Chu E, Busam K, Sondak V, Messina J, Puig S, Colebatch A, Coughlin C, Berrebi K, Laetsch T, Mitchell S, Seynnaeve B. Evaluation and Surgical Management of Pediatric Cutaneous Melanoma and Atypical Spitz and Non-Spitz Melanocytic Tumors (Melanocytomas): A Report From Children's Oncology Group. Journal Of Clinical Oncology 2024, 43: 1157-1167. PMID: 39365959, PMCID: PMC11908957, DOI: 10.1200/jco.24.01154.Peer-Reviewed Original ResearchSentinel lymph node biopsyAtypical Spitz tumorsCutaneous melanomaSpitz tumorsRe-ExcisionSurgical managementMelanocytic tumorsSurgical management of cutaneous melanomaManagement of cutaneous melanomaNational Comprehensive Cancer Network guidelinesLymph node biopsyDefinitive surgical treatmentProgression to CMChildren's Oncology GroupDiagnosis of CMNode biopsyExcisional biopsyOncology GroupMalignant potentialSurgical treatmentNetwork guidelinesBiopsyClinicopathological evaluationCohort studyMelanocytic neoplasmsGP100 expression is variable in intensity in melanoma
Mann J, Hasson N, Su D, Adeniran A, Smalley K, Djureinovic D, Jilaveanu L, Schoenfeld D, Kluger H. GP100 expression is variable in intensity in melanoma. Cancer Immunology, Immunotherapy 2024, 73: 191. PMID: 39105816, PMCID: PMC11303354, DOI: 10.1007/s00262-024-03776-5.Peer-Reviewed Original ResearchConceptsGp100 expressionCutaneous melanomaTreatment of cutaneous melanomaAdvanced cutaneous melanomaT-cell engagersImprove patient selectionMetastatic melanomaUveal melanomaMetastatic samplesPatient selectionClinical trialsMelanomaQuantitative immunofluorescence methodGp100Improve outcomesImmunofluorescence methodTherapeutic intentDrugCellular productsExpressionTebentafuspImmunohistochemistryPrimary Tumor Characteristics as Biomarkers of Immunotherapy Response in Advanced Melanoma: A Retrospective Cohort Study
Goodman R, Jung S, Fletcher K, Burnette H, Mohyuddin I, Irlmeier R, Ye F, Johnson D. Primary Tumor Characteristics as Biomarkers of Immunotherapy Response in Advanced Melanoma: A Retrospective Cohort Study. Cancers 2024, 16: 2355. PMID: 39001417, PMCID: PMC11240575, DOI: 10.3390/cancers16132355.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsRetrospective cohort studyCutaneous melanomaAssociated with responseMelanoma patientsImmunotherapy responseTreated with immune checkpoint inhibitorsCohort studySingle-center retrospective cohort studyAssociated with shorter PFSAnti-PD-1 monotherapyAssociated with inferior outcomesBiomarkers of immunotherapy responsePrimary tumor characteristicsPrimary tumor featuresAdvanced melanoma patientsResponse to immunotherapySingle-center designCheckpoint inhibitorsShorter PFSAdvanced melanomaTumor characteristicsPrimary melanomaMutation statusMetastatic stageSkipped sentinel lymph node basin in a patient with forearm cutaneous melanoma: A case report
Noel O, Clune J. Skipped sentinel lymph node basin in a patient with forearm cutaneous melanoma: A case report. Oncology Letters 2024, 27: 233. PMID: 38586207, PMCID: PMC10996031, DOI: 10.3892/ol.2024.14366.Peer-Reviewed Original ResearchLymph nodesMalignant melanomaDrainage to lymph nodesRight supraclavicular lymph nodeSentinel lymph node basinSentinel lymph node biopsyManagement of malignant melanomaLymph node basinSupraclavicular lymph nodesLymph node biopsyRegional lymph nodesLymph node localizationConventional nodal basinsCutaneous lymphoscintigraphyNode basinNode biopsyAxillary dissectionLymphatic mappingNodal basinsCutaneous melanomaCase reportUnique presentationDisease localizationUnique caseMelanoma
2023
627 The effect of LNS8801 in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma
Rodon J, Chaney M, Cohen J, Garyantes T, Lin J, Ishizuka J, Mita A, Mita M, Muller C, Natale C, Orloff M, Papadopoulos K, Patel S, Shoushtari A. 627 The effect of LNS8801 in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma. 2023, a716-a716. DOI: 10.1136/jitc-2023-sitc2023.0627.Peer-Reviewed Original ResearchSociety for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
Pavlick A, Ariyan C, Buchbinder E, Davar D, Gibney G, Hamid O, Hieken T, Izar B, Johnson D, Kulkarni R, Luke J, Mitchell T, Mooradian M, Rubin K, Salama A, Shirai K, Taube J, Tawbi H, Tolley J, Valdueza C, Weiss S, Wong M, Sullivan R. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0. Journal For ImmunoTherapy Of Cancer 2023, 11: e006947. PMID: 37852736, PMCID: PMC10603365, DOI: 10.1136/jitc-2023-006947.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsClinical practice guidelinesCutaneous melanomaTreatment of melanomaPractice guidelinesProlongs recurrence-free survivalCancer clinical practice guidelinesCell death protein 1Metastatic cutaneous melanomaBispecific T cell engager (BiTE) therapyChemotherapy-resistant diseaseRecurrence-free survivalDeath protein 1Long-term followManagement of patientsSpecial patient populationsImmunotherapy of cancerConsensus-based recommendationsPossibility of cureUnique toxicity profileQuality of lifeIntratumoral immunotherapyNeoadjuvant strategiesAdvanced diseaseBrain metastases1101P The effect of LNS8801 in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma
Rodon J, Chaney M, Cohen J, Garyantes T, Ishizuka J, Lin J, Lorusso P, Mita A, Mita M, Muller C, Natale C, Orloff M, Papadopoulos K, Patel S, Shoushtari A. 1101P The effect of LNS8801 in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma. Annals Of Oncology 2023, 34: s663. DOI: 10.1016/j.annonc.2023.09.2235.Peer-Reviewed Original ResearchImmune Inhibitory Molecule PD-1 Homolog (VISTA) Colocalizes with CD11b Myeloid Cells in Melanoma and Is Associated with Poor Outcomes
Vesely M, Kidacki M, Gaule P, Gupta S, Chan N, Han X, Yeung J, Chen L. Immune Inhibitory Molecule PD-1 Homolog (VISTA) Colocalizes with CD11b Myeloid Cells in Melanoma and Is Associated with Poor Outcomes. Journal Of Investigative Dermatology 2023, 144: 106-115.e4. PMID: 37562584, PMCID: PMC11966651, DOI: 10.1016/j.jid.2023.07.008.Peer-Reviewed Original ResearchConceptsCD11b myeloid cellsImmune inhibitory moleculesPD-L1 expressionVISTA expressionMyeloid cellsFuture potential therapeutic targetsPD-L1/B7Tumor microenvironmentInhibitory moleculesMultiplexed quantitative immunofluorescencePrimary cutaneous melanomaImmunosuppressive tumor microenvironmentNegative prognostic biomarkerCurrent clinical trialsPotential therapeutic targetCause mortalityCritical cell typesPD-L1Poor outcomeTreatment of cancerMelanoma recurrenceCutaneous melanomaClinical trialsPrognostic biomarkerT cellsDeep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases
Chatziioannou E, Roßner J, Aung T, Rimm D, Niessner H, Keim U, Serna-Higuita L, Bonzheim I, Cuellar L, Westphal D, Steininger J, Meier F, Pop O, Forchhammer S, Flatz L, Eigentler T, Garbe C, Röcken M, Amaral T, Sinnberg T. Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases. EBioMedicine 2023, 93: 104644. PMID: 37295047, PMCID: PMC10363450, DOI: 10.1016/j.ebiom.2023.104644.Peer-Reviewed Original ResearchConceptsTumor-infiltrating lymphocytesMultiple Cox regressionMelanoma-specific survivalCox regressionTumor thicknessCutaneous melanomaPrimary melanomaAssessment of TILsPD-1 checkpoint inhibitionSignificant unfavourable prognostic factorLonger progression-free survivalDistant metastasis-free survivalSimple Cox regressionUnfavourable survival outcomeFirst-line therapyProgression-free survivalUnfavourable prognostic factorCutaneous melanoma patientsMetastasis-free survivalPresence of ulcerationPrimary cutaneous melanomaCox regression modelPrimary melanoma samplesPrimary tissuesOverall survivalA phase 2/3 trial in progress on tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A*02:01+ patients with previously treated advanced non-uveal melanoma (TEBE-AM).
Davar D, Ikeguchi A, Buchbinder E, Shoushtari A, Seedor R, Bernicker E, Weiss S, Daniels G, Panella T, Ryan H, Goodall H, Sullivan R. A phase 2/3 trial in progress on tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A*02:01+ patients with previously treated advanced non-uveal melanoma (TEBE-AM). Journal Of Clinical Oncology 2023, 41: tps9594-tps9594. DOI: 10.1200/jco.2023.41.16_suppl.tps9594.Peer-Reviewed Original ResearchMetastatic cutaneous melanomaMetastatic uveal melanomaAdvanced melanomaInvestigator's choicePrimary endpointDual primary endpointsOverall survival benefitPhase 3 trialSimilar patient populationsPhase 2/3 trialIC armOS benefitPrior ipilimumabRECIST responseInhibitor regimenSupportive careSurvival benefitCare therapyAnti-CTLA4CtDNA levelsTumor burdenInvestigational agentsPatient populationCutaneous melanomaClinical trialsEarly Detection and Prognostic Assessment of Cutaneous Melanoma
Kashani-Sabet M, Leachman S, Stein J, Arbiser J, Berry E, Celebi J, Curiel-Lewandrowski C, Ferris L, Grant-Kels J, Grossman D, Kulkarni R, Marchetti M, Nelson K, Polsky D, Seiverling E, Swetter S, Tsao H, Verdieck-Devlaeminck A, Wei M, Bar A, Bartlett E, Bolognia J, Bowles T, B. K, Chu E, Hartman R, Hawryluk E, Jampel R, Karapetyan L, Kheterpal M, Lawson D, Leming P, Liebman T, Ming M, Sahni D, Savory S, Shaikh S, Sober A, Sondak V, Spaccarelli N, Usatine R, Venna S, Kirkwood J. Early Detection and Prognostic Assessment of Cutaneous Melanoma. JAMA Dermatology 2023, 159: 545-553. PMID: 36920356, PMCID: PMC11225588, DOI: 10.1001/jamadermatol.2023.0127.Peer-Reviewed Original ResearchConceptsRisk-stratified approachCutaneous melanomaGEP scorePrognostic assessmentGene expression profile testingMelanoma screeningEarly detectionLow-risk histologyNegative nodal statusDelphi consensus methodReflectance confocal microscopyNodal statusSentinel lymphAdvanced melanomaHistologic featuresScreening eventsScreening practicesConsensus statementConsensus recommendationsSkin lesionsDermoscopic examinationGEP testingConsensus conferenceMelanocytic skin lesionsClinical settingPredictive accuracy of elevated mitotic rate on lymph node positivity and recurrence in thin melanomas
Ly C, Blaha O, Wei W, Galan A, Kluger H, Ariyan S, Olino K, Clune J. Predictive accuracy of elevated mitotic rate on lymph node positivity and recurrence in thin melanomas. Frontiers In Oncology 2023, 12: 1077226. PMID: 36686728, PMCID: PMC9853390, DOI: 10.3389/fonc.2022.1077226.Peer-Reviewed Original ResearchMelanoma-specific mortalityElevated mitotic rateLymph node positivityMitoses/Mitotic rateT2 tumorsNode positivityThin melanomasSentinel lymph node positivityImportant prognostic factorSingle academic centerPrimary cutaneous melanomaLow mitotic ratePositive SLNNon-ulcerated lesionsSLN biopsyT4 tumorsPatient demographicsPrognostic factorsSLN positivityRetrospective reviewTumor characteristicsBreslow thicknessCutaneous melanomaT category
2022
Indoor Versus Outdoor: Does Occupational Sunlight Exposure Increase Melanoma Risk? A Systematic Review
Maduka R, Tai K, Gonsai R, DeWalt N, Chetty A, Brackett A, Olino K, Schneider E, Ahuja V. Indoor Versus Outdoor: Does Occupational Sunlight Exposure Increase Melanoma Risk? A Systematic Review. Journal Of Surgical Research 2022, 283: 274-281. PMID: 36423476, DOI: 10.1016/j.jss.2022.10.025.Peer-Reviewed Original ResearchConceptsCutaneous melanomaSystematic reviewOutdoor occupationsGrading of RecommendationsChronic occupational exposureRetrospective case controlInternational Prospective RegisterNew cancer casesMeta-Analyses (PRISMA) guidelinesPreferred Reporting ItemsInitial database searchFull-text screeningCutaneous melanoma developmentEvidence certaintyCohort studyScreening recommendationsCommon cancerRisk factorsStudy protocolProspective RegisterCase ascertainmentCancer casesOccupational exposureStudy qualityCase controlClinical Practice Guidelines on Sentinel Lymph Node Biopsy for Melanoma: A Systematic Review and Quality Appraisal Using the AGREE II Instrument
De Ravin E, Suresh N, Romeo D, Lu J, Shah M, Karakousis G, Moreira A, Rajasekaran K. Clinical Practice Guidelines on Sentinel Lymph Node Biopsy for Melanoma: A Systematic Review and Quality Appraisal Using the AGREE II Instrument. Annals Of Surgical Oncology 2022, 29: 8364-8372. PMID: 36121581, DOI: 10.1245/s10434-022-12525-w.Peer-Reviewed Original ResearchConceptsClinical practice guidelinesAGREE II instrumentPractice guidelinesNegative regional lymph nodesAvailable clinical practice guidelinesSentinel lymph node biopsyGuideline development teamsRole of lymphLymph node biopsyManagement of melanomaPresence of metastasesRegional lymph nodesAppraisal of GuidelinesRegional disease controlAGREE II domainsInvasive surgical proceduresAdjuvant therapyNode biopsySentinel lymphLymph nodesCutaneous melanomaPatient prognosisThick melanomasInclusion criteriaSurgical proceduresSmall bowel obstruction caused by hemorrhagic metastatic melanoma: case report and literature review
Wu F, Lee MS, Kim DE. Small bowel obstruction caused by hemorrhagic metastatic melanoma: case report and literature review. Journal Of Surgical Case Reports 2022, 2022: rjac395. PMID: 36071730, PMCID: PMC9444292, DOI: 10.1093/jscr/rjac395.Peer-Reviewed Original ResearchSmall bowel obstructionSmall bowel resectionBowel obstructionBowel resectionMetastatic melanomaGastrointestinal tractRecurrent gastrointestinal bleedingSmall intestinal melanomaPrimary cutaneous melanomaCause of deathGastrointestinal metastasesIntestinal melanomaGastrointestinal bleedingGastrointestinal hemorrhageDiagnostic laparoscopyRadionuclide scansAdditional metastasesActive hemorrhageCommon malignancyPathologic examinationCase reportCommon cancerCutaneous melanomaPrior historySkin cancerLB998 Lymph node delivery of immunstimulatory agent monophosphoryl lipid A via bioadhesive nanoparticles in the treatment of cutaneous melanoma
Chang J, Shin K, Lewis J, Suh H, Bosenberg M, Saltzman W, Girardi M. LB998 Lymph node delivery of immunstimulatory agent monophosphoryl lipid A via bioadhesive nanoparticles in the treatment of cutaneous melanoma. Journal Of Investigative Dermatology 2022, 142: b29. DOI: 10.1016/j.jid.2022.05.1024.Peer-Reviewed Original ResearchA novel 7 RNA-based signature for prediction of prognosis and therapeutic responses of wild-type BRAF cutaneous melanoma
Sun R, Liu Y, Lei C, Tang Z, Lu L. A novel 7 RNA-based signature for prediction of prognosis and therapeutic responses of wild-type BRAF cutaneous melanoma. Biological Procedures Online 2022, 24: 7. PMID: 35751033, PMCID: PMC9233353, DOI: 10.1186/s12575-022-00170-2.Peer-Reviewed Original ResearchCutaneous melanomaLack of therapeutic optionsPrediction of prognosisHigh-risk groupBackgroundThe prognosisMalignancy of cancerTherapeutic optionsTherapeutic responseClinical factorsPrognosisCellular proliferationClinical practicePatientsPI3K/AKT/mTOR pathwayTCGA databaseMelanomaUp-regulatedFunctional analysisPotential drug targetsMolecular mechanismsBioinformatic evidenceDrug targetsRNA splicingTranscriptional profiling of macrophages in situ in metastatic melanoma reveals localization-dependent phenotypes and function
Martinek J, Lin J, Kim KI, Wang VG, Wu TC, Chiorazzi M, Boruchov H, Gulati A, Seeniraj S, Sun L, Marches F, Robson P, Rongvaux A, Flavell RA, George J, Chuang JH, Banchereau J, Palucka K. Transcriptional profiling of macrophages in situ in metastatic melanoma reveals localization-dependent phenotypes and function. Cell Reports Medicine 2022, 3: 100621. PMID: 35584631, PMCID: PMC9133468, DOI: 10.1016/j.xcrm.2022.100621.Peer-Reviewed Original ResearchConceptsMonocytes/macrophagesDendritic cellsMetastatic melanomaMelanoma cellsMetastatic cutaneous melanomaRegulation of toleranceSpecific transcriptional signatureTranscriptional profilingGene setsLaser capture microdissectionCell-based therapiesTranscriptional signatureCutaneous melanomaDC functionPatient outcomesMetastatic cancerTumor nestsTCGA cohortImmune functionCandidate biomarkersCD14Stromal macrophagesTumor siteTherapeutic opportunitiesAntigen captureAutoimmune retinopathy with associated anti-retinal antibodies as a potential immune-related adverse event associated with immunotherapy in patients with advanced cutaneous melanoma: case series and systematic review
Heng JS, Kim JM, Jones DK, Stoessel KM, Weiss SA, Sznol M, Kluger HM, Walter SD, Silverstein NA, Pointdujour-Lim R. Autoimmune retinopathy with associated anti-retinal antibodies as a potential immune-related adverse event associated with immunotherapy in patients with advanced cutaneous melanoma: case series and systematic review. BMJ Open Ophthalmology 2022, 7: e000889. PMID: 35047671, PMCID: PMC8724805, DOI: 10.1136/bmjophth-2021-000889.Peer-Reviewed Original ResearchConceptsAdvanced cutaneous melanomaAnti-retinal antibodiesImmune-related adverse eventsAutoimmune retinopathyCutaneous melanomaNivolumab immunotherapySystematic reviewAdverse eventsMucosal melanomaAcute exudative polymorphous vitelliform maculopathyPotential immune-related adverse eventsBilateral visual field lossNew visual symptomsImmune checkpoint inhibitionRetrospective chart reviewCutaneous melanoma patientsVaried clinical manifestationsVisual field lossComplete ophthalmic examinationScreening of patientsMeta-Analyses (PRISMA) guidelinesPreferred Reporting ItemsVitelliform maculopathyChart reviewFunduscopic changesSentinel Lymph Node Biopsy Positivity in Patients With Acral Lentiginous and Other Subtypes of Cutaneous Melanoma
Cheraghlou S, Ugwu N, Girardi M. Sentinel Lymph Node Biopsy Positivity in Patients With Acral Lentiginous and Other Subtypes of Cutaneous Melanoma. JAMA Dermatology 2022, 158: 51-58. PMID: 34878492, PMCID: PMC8655663, DOI: 10.1001/jamadermatol.2021.4812.Peer-Reviewed Original ResearchConceptsAcral lentiginous melanomaNational Cancer DatabaseClinical stage IBSLN positivityStage IBSentinel lymphCutaneous melanomaPositivity rateMalignant melanomaHigh riskSentinel lymph node statusAJCC Cancer Staging ManualClinical stage IRetrospective cohort studySignificant prognostic factorsLymph node statusCancer Staging ManualMultivariable logistic regressionHigher positivity rateAJCC clinical stageCohort studySLN statusPrognostic factorsSuch patientsStaging Manual
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply